Lakeside Holding Limited filings document the regulatory record of a Nasdaq-listed emerging growth company with common stock registered under symbol LSH. The company’s disclosures cover its cross-border logistics and pharmaceutical distribution operations, material events reported on Form 8-K, late-filing notices for quarterly reports, and governance matters submitted to stockholder votes.
Proxy materials describe director elections, amendments to charter and bylaw provisions, authorized common and preferred stock proposals, share-issuance approvals, quorum and voting-threshold matters, and other capital-structure governance items. The filing record also includes Nasdaq continued-listing notices, board changes, annual and special meeting results, and related disclosure controls for a public operating company.
Lakeside Holding (Nasdaq: LSH) filed a Form 8-K disclosing that on June 24 2025 it executed a Securities Purchase Agreement with several investors for a private placement of 3,000,000 common shares at $1.00 per share, generating approximately $3.0 million in gross proceeds.
The shares are being issued under the Section 4(a)(2)/Regulation S exemptions and therefore are unregistered securities subject to transfer restrictions. Proceeds are earmarked for general corporate purposes. The agreement contains customary representations, warranties and covenants and is included as Exhibit 10.1.
The filing also triggers Item 3.02 disclosure for unregistered sales of equity securities. No additional financial statements, pro-formas, or risk factors were provided, and no other material events were reported.